Antinol® Latest Studies
Sorted by recent
Filter Studies by Smart Tags
Bone & JointCardiovascularCase Study & ProceedingCatDogEAB 277™EfficacyExotic PetImmunologyNeuro & BehaviorOphthalmologyOralRabbitRenalRespiratoryRodentSafetySkinUTISmart Search
Effects of PCSO-524® (Antinol®) Supplementation during 12 Months Follow-up in 2 Cats with Cystitis and Chronic Renal Disease
Two female cats, spayed, lived in the same house, aged 17 years weighted 2.2 kg and 10 years 4.4 kg, were having chronic renal failure and concurrent cystitis.
Both cats were treated with fluid therapy intravenously in the early period and later subcutaneously. The diet was changed to diet formulated for cats with renal failure (Hill’s Prescription diet k/d) for both cats. Avastamine (RenAvastTM) 1 capsule bid for 1 month, Cystaid® cat (Acetyl 0-Glucosamine: NAG125 mg) l capsule bid for 1 month, and PCSO-524® (Vetz Petz Antinol®) 1 capsule sid continuously were prescribed for the first cat. The second cat received only PCSO-524® (Vetz Petz Antinol®) 1 capsule sid continuously.
The treatment results showed general health improvement, weight gain (2.6 kg and 5.1 kg in the first and second cat, respectively), less hair loss, decreased degree of polydipsia and polyuria, and improvement of blood parameters.
No adverse effect of the continuous treatment was found after 18 and 13 months in the first and second cat, respectively.
Effects of PCSO-524® on Inflammation Control in Cats with Chronic Renal Disease after Keratectomy and Conjunctival Pedicle Graft for Treatment of Corneal Sequestrum from Indolent Ulcer
A female spayed cat aged 13 years with chronic renal disease later affected with indolent ulcer, and consequently followed by corneal sequestrum.
After azotemia was controlled, the cat was surgically treated with keratectomy that used conjunctival pedicle graft for suture closure.
The cat received 4mg/kg Tolfenamic acid (Tolfedine®, Vetoquinol, Best Agro; Thailand) for 3 days, 2.5 mg/kg Doxycycline monohydrate (Vibravet®, Zoetis, Thailand) for 2 weeks and 1 tablet per day of New Zealand Green-lipped mussel extract, PCSO-524® (Vetz Petz Antinol®, DKSH, Thailand) for long-term control of inflammation.
The latter was used as an antioxidant and alternative to Non-steroid, which is a contradiction for chronic renal failure.
The cat showed decreased severity of inflammation, normal clinical symptoms, and fine control of azotemia.
It is concluded that PCSO-524® (Vetz Petz Antinol®) can be used to support long-term anti-inflammation treatment and reduce the damage in cats with medical contraindication due to chronic renal disease
The Effects of PCSO-524 Extract on Vital Signs, Complete Blood Count, and Blood Chemistry in Clinically-Healthy Normal Cats
Chronic pain is commonly caused by degenerative disease, which is under diagnosed in cats.
PCSO-524 is an extract of Perna canaliculus, a known source of Omega-3 polyunsaturated fatty acids (PUFAs) with anti-inflammatory properties. Lipids extracted from the New Zealand green-lipped mussel (NZGLM) contain a complex mixture of mainly phospholipids (PL, 57-79%), triglycerides (TG, 10-25%), free fatty acids (FFA, 7-12%) and sterols (ST, 12-18%)
PCSO-524 is a source of omega-3 polyunsaturated fatty acids with anti-inflammatory properties commonly used to treat osteoarthritis in human beings and dogs.
The purpose of this study was to study the effects of PCSO-524 extract on vital signs, completed blood count, and blood chemistry in clinically-healthy normal cats.
Antinol® Case Study Contest 2016
The 10 Case Studies from Antinol® Case Study Contest of 2016.
1st Winning Awards
1) Effects of PCSO-524® on Inflammation Control in Cats with Chronic Renal Disease after Keratectomy and Conjunctival Pedicle Graft for Treatment of Corneal Sequestrum from Indolent Ulcer
2) The Use of Cyclosporine and PCSO-524® in the Treatment of Alopecia and Dermatitis due to Sebaceous Adenitis in Rabbits
2nd Winning Awards
3) Use of PCSO-524® in Combination with Prednisolone for Treatment of Spinal Cord Injury from Disc Protrusion in Dogs
4) Effects of PCSO-524® on Treatment of Cranial Cruciate Ligament Rupture in Dogs after Tibial Plateau Leveling Osteotomy (TPLO) and Physical Rehabilitation
5) The Treatment of Medial Coronoid Disease in a Seven Months Old Labrador Retriever
3rd Winning Awards
6) A Study of Efficacy and Safety of PCSO-524® (Antinol®l in Treatment of Medial Patellar Luxation and Cranial Cruciate Ligament Rupture in a Yorkshire Terrier Dog
7) Effects of PCSO-524® (Antinol®l Supplementation during 12 Months Follow-up in 2 Cats with Cystitis and Chronic Renal Disease
8) Use of PCSO-524® (Antinol®) for Treatment of Nervous Disorder Caused by Car Accident and Hip Osteoarthritis in Geriatric Cats
9) PCSO-524® as Supportive Therapy for Generalized Alopcia in Guinea Pigs
10) Use of Acupuncture in Combination with PCS0-524® (Antinol®l for Treatment of Hindlimb Paresis in Prairie Dogs
Updated Study Topics
New researches and publications related to PCSO-524® and its result in clnical test submitted by veterinarians on the global conferences every year and the data keeps growing with more studies conducted